Randomized Clinical Trial of Surgical vs. Percutaneous vs. Hybrid Revascularization in Multivessel Coronary Artery Disease: Residual Myocardial Ischemia and Clinical Outcomes at One Year-Hybrid coronary REvascularization Versus Stenting or Surgery (HREVS).
Vladimir GanyukovNikita KocherginAleksandr ShilovRoman TarasovJan SkupienWojciech SzotAleksandr N KokovVadim PopovKirill KozyrinOlga BarbarashLeonid BarbarashPiotr MusialekPublished in: Journal of interventional cardiology (2020)
In this first randomized controlled study comparing CABG, HCR, and MV-PCI, residual myocardial ischemia and MACCE were similar at 12 months. There was no midterm indication of any added value of HCR. Hospital stay and sick-leave duration were shortest with MV-PCI. While longer-term follow-up is warranted, these findings may impact patient and physician choices and healthcare resources utilization. This trial is registered with NCT01699048.
Keyphrases
- coronary artery disease
- percutaneous coronary intervention
- coronary artery bypass
- coronary artery bypass grafting
- antiplatelet therapy
- healthcare
- phase iii
- st segment elevation myocardial infarction
- double blind
- st elevation myocardial infarction
- acute myocardial infarction
- minimally invasive
- phase ii
- left ventricular
- open label
- clinical trial
- cardiovascular events
- placebo controlled
- acute coronary syndrome
- primary care
- preterm infants
- emergency department
- study protocol
- case report
- aortic stenosis
- ultrasound guided
- coronary artery
- acute care
- gestational age
- social media
- type diabetes
- drug induced
- adverse drug
- cardiovascular disease